[Ibopamine--clinical results].
Recently, major advances have been made in the therapy of chronic congestive heart failure. New vasodilatory and positive inotropic drugs as well as specific antagonists to activated neurohormones have added new therapeutic dimensions. Dopaminergic stimulation, which has been used in acute heart failure for many years has now been introduced with the new substance ibopamine into the therapy of chronic heart failure. The therapeutic efficacy of new drugs in the treatment of chronic congestive heart failure has to be evaluated in terms of their prognostic and therapeutic impact for improvement and symptomatology, which sometimes does not necessarily lead to improvement of prognosis. Ibopamine has potential in improving prognosis by its major effects: vasodilatation, decrease in vasoactive hormones and improvement in renal blood flow and water diuresis. In the long-term therapy of chronic congestive heart failure ibopamine has been useful in mobilization of edema in acute decompensation, improvement of symptoms according to the New York Heart Classification and of exercise tolerance. In addition improvement of hemodynamics with an increase in cardiac output, a decrease in filling pressures and in peripheral resistance has been demonstrated. Efficacy of diuretics is improved and ibopamine has been a valuable adjunct in the pre-operative therapy before cardiac transplantation. Major positive inotropic effects in the usual dose of 100 mg tid, as well as other potentially dangerous effects of beta-receptor-stimulation (such as malignant, ventricular arrhythmias) can be largely excluded. Historically, controls of patients with heart failure of similar severity do not suggest any unfavorable effect of this drug on prognosis.